BrightGene Bio-Medical Hits Day Low at CNY 30.17 Amid Price Pressure

BrightGene Bio-Medical Technology Co., Ltd. experienced a significant decline today, with its stock price dropping by 5.88% to reach an intraday low of CNY 30.17. This performance stands in stark contrast to the China Shanghai Composite, which saw a modest gain of 0.44% on the same day. Over the past week, BrightGene's stock has decreased by 9.45%, and its performance over the last month reflects a substantial decline of 35.77%. Year-to-date, the stock has fallen by 32.84%, while its one-year performance shows a decrease of 39.18%. In comparison, the China Shanghai Composite has gained 3.62% year-to-date and 18.93% over the past year. The company, operating in the Pharmaceuticals & Biotechnology sector, has faced challenges, including a high debt-to-equity ratio and declining net sales. Its return on equity stands at a low 1.44%, indicating limited profitability. Additionally, BrightGene has reported negative results for the last six consecutive quarters, further highlighting its current financial difficulties.